dc.contributor.author | Conroy, Melissa | en |
dc.date.accessioned | 2024-05-24T14:10:44Z | |
dc.date.available | 2024-05-24T14:10:44Z | |
dc.date.issued | 2021 | en |
dc.date.submitted | 2021 | en |
dc.identifier.citation | O'Donovan, Davern M., Donlon N.E., Lysaght J and M.J. Conroy, Chemokine-targeted therapies: An opportunity to remodel immune profiles in gastro-oesophageal tumours, Cancer Letters, 2021 | en |
dc.identifier.issn | PMID: 34506844 | en |
dc.identifier.other | Y | en |
dc.identifier.uri | http://hdl.handle.net/2262/108480 | |
dc.description | PUBLISHED | en |
dc.description.abstract | Immunotherapies are transforming outcomes for many cancer patients and are quickly becoming the fourth pillar of cancer therapy. However, their efficacy of only ∼25% in gastro-oesophageal cancer has been disappointing. This is attributed to factors such as insufficient patient stratification and the pro-tumourigenic immune landscape of gastro-oesophageal tumours. The chemokine profiles of solid tumours and the availability of effector immune cells greatly influence the immune infiltrate, producing 'cold' or 'immune-excluded' tumours in which immunotherapies are unable to reinvigorate the immune response. Other biological functions for chemokines have emerged, such as promoting cell survival, polarising T cell responses, and supporting several hallmarks of cancer. Therefore, chemokine networks may be exploited with therapeutic intent to mobilise and polarise anti-tumour immune cells, with further utility as combination treatments to augment the efficacy of current cancer immunotherapies. Few studies have demonstrated the clinical benefit of chemokine-targeted therapies as monotherapies, and this review proposes their consideration as combination treatments. Herein, we explore the anti-tumour and pro-tumour implications of chemokine signalling in gastro-oesophageal cancer and discuss their value as prognostic and predictive biomarkers in response to treatment. | en |
dc.language.iso | en | en |
dc.relation.ispartofseries | Cancer Letters | en |
dc.rights | Y | en |
dc.subject | Chemokine receptor antagonist; Combination treatment; Immunotherapy; Tumour immunology; Tumour microenvironment | en |
dc.title | Chemokine-targeted therapies: An opportunity to remodel immune profiles in gastro-oesophageal tumours | en |
dc.type | Journal Article | en |
dc.type.supercollection | scholarly_publications | en |
dc.type.supercollection | refereed_publications | en |
dc.identifier.peoplefinderurl | http://people.tcd.ie/meconroy | en |
dc.identifier.rssinternalid | 265965 | en |
dc.identifier.doi | https://doi.org/10.1016/j.canlet.2021.09.005 | en |
dc.rights.ecaccessrights | openAccess | |
dc.subject.TCDTheme | Cancer | en |
dc.subject.TCDTheme | Identities in Transformation | en |
dc.subject.TCDTag | Biomedical sciences | en |
dc.subject.TCDTag | CANCER | en |
dc.subject.TCDTag | Tumour immunology and immunotherapy | en |
dc.identifier.rssuri | https://doi.org/10.1016/j.canlet.2021.09.005 | en |
dc.identifier.orcid_id | 0000-0002-3822-0442 | en |
dc.status.accessible | N | en |